ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0730

Levels of Disease Activity and Their Relationship With Health-Related Quality of Life In ANCA-Associated Vasculitis Patients: Data from the Almenara Vasculitis Cohort

Victor Pimentel-Quiroz1, Alvaro Oyarce-Calderón2, Allison Figueroa-Sánchez3, Leonor León-Yaurimucha3, Rocío Gamboa-Cárdenas4, Zoila Rodríguez-Bellido5, Risto Perich-Campos6, Graciela Alarcón7 and Manuel Ugarte-Gil8, 1Universidad Científica del Sur, San Isidro, Peru, 2Hospital Nacional Guillermo Almenara Irigoyen, San Miguel, Lima, Peru, 3Universidad Científica del Sur, Lima, Peru, 4Universidad Científica del Sur, Lima, Peru, 5Hospital Nacional Guillermo Almenara Irigoyen; Universidad Nacional Mayor de San Marcos, Lima, Peru, 6Hospital Nacional Guillermo Almenara Irigoyen; Universidad Nacional Mayor de San Marcos, La Molina, Peru, 7The University of Alabama at Birmingham, Oakland, CA, 8Universidad Cientifica del Sur, Lima, Peru

Meeting: ACR Convergence 2025

Keywords: ANCA associated vasculitis, quality of life, Vasculitis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, October 26, 2025

Title: (0711–0730) Vasculitis – ANCA-Associated Poster I

Session Type: Poster Session A

Session Time: 10:30AM-12:30PM

Background/Purpose: It is known that health-related quality of life (HRQoL) in patients with ANCA-associated vasculitis (AAV) is impaired. Categories of disease activity levels have been proposed for these patients; however, it is unknown whether these categories might impact these patients’ HRQoL. Therefore, the aim of this study is to determine the relationship between HRQoL and levels of disease activity in AAV patients.

Methods: We included patients from the Almenara Vasculitis cohort who had at least one visit between December 2022 and November 2024 and had a diagnosis of either microscopic polyangiitis (MPA) or granulomatosis with polyangiitis. Sociodemographic features, disease activity measured with the Birmingham Vasculitis Activity Score version 3 score, damage measured with the Vasculitis Damage Index score, and HRQoL assessed by the AAV-PRO (Spanish version) and the Short Form 36 (SF-36), were obtained. Levels of disease activity were categorized as complete remission, clinical remission off therapy (CROffT), clinical remission on therapy (CRonT), low disease activity (LDA) and active disease; these definitions are shown in Table 1. For these analyses, complete remission, CROffT and CRonT were examined together due to the relatively small sample size for each of them individually. Unadjusted and adjusted linear regression models were performed; possible confounders included in the adjusted model were age, sex, ethnicity, education level, socioeconomic status, type of diagnosis, ANCA status, vasculitis damage index, current prednisone dose, current immunosuppressive drug.

Results: Eighty-four patients were enrolled; female sex and MPA were more frequent. In the adjusted analyses, regarding the SF-36, active disease was associated negatively with general health, role emotional and the mental component summary domains; likewise, LDA was negatively associated with role physical. Regarding the AAV-PRO, active disease was positively associated with the treatment side effects domain.

Conclusion: Active disease impacted in the HRQoL as assessed by the-SF36 and the AAV-PRO questionnaires, although the first one was more associated with levels of disease activity.

Supporting image 1Table 1. Definitions of levels of disease activity.

Supporting image 2Table 2. Unadjusted and adjusted analyses.


Disclosures: V. Pimentel-Quiroz: Biopas, 6, Pfizer, 6, Roche, 6, technofarm, 6; A. Oyarce-Calderón: None; A. Figueroa-Sánchez: None; L. León-Yaurimucha: None; R. Gamboa-Cárdenas: None; Z. Rodríguez-Bellido: None; R. Perich-Campos: None; G. Alarcón: None; M. Ugarte-Gil: AstraZeneca, 1, 6, Ferrer, 1, GlaxoSmithKlein(GSK), 6, Janssen, 5, technofarma, 1.

To cite this abstract in AMA style:

Pimentel-Quiroz V, Oyarce-Calderón A, Figueroa-Sánchez A, León-Yaurimucha L, Gamboa-Cárdenas R, Rodríguez-Bellido Z, Perich-Campos R, Alarcón G, Ugarte-Gil M. Levels of Disease Activity and Their Relationship With Health-Related Quality of Life In ANCA-Associated Vasculitis Patients: Data from the Almenara Vasculitis Cohort [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/levels-of-disease-activity-and-their-relationship-with-health-related-quality-of-life-in-anca-associated-vasculitis-patients-data-from-the-almenara-vasculitis-cohort/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/levels-of-disease-activity-and-their-relationship-with-health-related-quality-of-life-in-anca-associated-vasculitis-patients-data-from-the-almenara-vasculitis-cohort/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology